Bevacizumab Clinical Trials

9 recruiting

Bevacizumab Trials at a Glance

10 actively recruiting trials for bevacizumab are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Phase 2 with 5 trials, with the heaviest enrollment activity in Guangzhou, Beijing, and Beijing. Lead sponsors running bevacizumab studies include Sun Yat-sen University, Ruijin Hospital, and Nanfang Hospital, Southern Medical University.

Browse bevacizumab trials by phase

Treatments under study

About Bevacizumab Clinical Trials

Looking for clinical trials for Bevacizumab? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Bevacizumab trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Bevacizumab clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 3

Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases

Brain MetastasesLung AdenocarcinomaWhole-Brain Radiotherapy+2 more
Sun Yat-sen University220 enrolled3 locationsNCT07481786
Recruiting
Phase 2

QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

BevacizumabHepatecellular CarcinomaRALOX-HAIC(Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin+3 more
Nanfang Hospital, Southern Medical University38 enrolled1 locationNCT07327788
Recruiting

Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma

Advanced Hepatocellular CarcinomaBevacizumabAnti-PD1/PDL1 Antibody
Sun Yat-sen University240 enrolled1 locationNCT06323382
Recruiting
Phase 2

Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

Colo-rectal CancerBevacizumabThird-line and Beyond Therapy+1 more
Ruijin Hospital50 enrolled2 locationsNCT07085169
Recruiting

Ate-Bev Early Response Prediction Model in Advanced HCC

Hepatocellular CarcinomaAtezolizumab-bevacizumabResponse Evaluation
Seoul National University Hospital170 enrolled1 locationNCT05763277
Recruiting
Not Applicable

dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma

ChemotherapyAdvanced Hepatocellular CarcinomaAtezolizumab+1 more
Sun Yat-sen University27 enrolled1 locationNCT06609863
Recruiting
Phase 1Phase 2

Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy

Neoadjuvant TreatmentRectal CancerRadiotherapy+1 more
Shanghai Minimally Invasive Surgery Center20 enrolled1 locationNCT05111860
Recruiting
Phase 2

Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

Hepatocellular CarcinomaBevacizumabAdebrelimab+2 more
The First Affiliated Hospital of Xiamen University71 enrolled1 locationNCT05970666
Recruiting
Not Applicable

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

Hepatocellular CarcinomaPulmonary MetastasesLiver Cancer Stage IV+3 more
Sun Yat-sen University80 enrolled2 locationsNCT06265350
Recruiting
Phase 2

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

CapecitabineTislelizumabBevacizumab+2 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences52 enrolled1 locationNCT05970302